Last reviewed · How we verify
Trabectedin and Pegylated Liposomal Doxorubicin
Trabectedin and Pegylated Liposomal Doxorubicin is a Small molecule drug developed by Grupo Español de Investigación en Cáncer de Ovario. It is currently in Phase 2 development.
At a glance
| Generic name | Trabectedin and Pegylated Liposomal Doxorubicin |
|---|---|
| Sponsor | Grupo Español de Investigación en Cáncer de Ovario |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer (PHASE2)
- Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma (PHASE2)
- Reprab Study: PLD + Trabectedin Rechallenge (PHASE2)
- Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
- An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trabectedin and Pegylated Liposomal Doxorubicin CI brief — competitive landscape report
- Trabectedin and Pegylated Liposomal Doxorubicin updates RSS · CI watch RSS
- Grupo Español de Investigación en Cáncer de Ovario portfolio CI
Frequently asked questions about Trabectedin and Pegylated Liposomal Doxorubicin
What is Trabectedin and Pegylated Liposomal Doxorubicin?
Trabectedin and Pegylated Liposomal Doxorubicin is a Small molecule drug developed by Grupo Español de Investigación en Cáncer de Ovario.
Who makes Trabectedin and Pegylated Liposomal Doxorubicin?
Trabectedin and Pegylated Liposomal Doxorubicin is developed by Grupo Español de Investigación en Cáncer de Ovario (see full Grupo Español de Investigación en Cáncer de Ovario pipeline at /company/grupo-espa-ol-de-investigaci-n-en-c-ncer-de-ovario).
What development phase is Trabectedin and Pegylated Liposomal Doxorubicin in?
Trabectedin and Pegylated Liposomal Doxorubicin is in Phase 2.